Actively Recruiting
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Led by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Updated on 2026-01-05
60
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
CONDITIONS
Official Title
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully understand this study and voluntarily sign the informed consent form.
- Age between 18 and 75 years, any gender.
- Diagnosis of advanced solid tumor confirmed by histopathology or cytology.
- Have failed or are intolerant to standard treatment for the tumor.
You will not qualify if you...
- Presence of central nervous system metastases as shown by medical history, CT, or MRI.
- Having any other malignancy within the past 5 years.
- Any condition or reason that the investigator judges makes participation unsuitable.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
S
Siqi Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here